Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he has put in place for the business, and the key issues of manufacturing and access.
Cell and gene therapies are truly transformative. With CAR-T therapies, we are entrusted to work with a patient’s own living T-cells. That is a huge responsibility as we have to know where the cells came from and monitor them carefully every step of the way
